tailieunhanh - o cáo hóa học:" Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats | Castilla-Cortázar et al. Journal of Translational Medicine 2011 9 103 http content 9 1 103 JOURNAL OF TRANSLATIONAL MEDICINE RESEARCH Open Access Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats 1 2 2 11 1 Inma Castilla-Cortázar María García-Fernández Gloria Delgado Juan E Puche Inma Sierra Rima Barhoum and Salvador González-Barón2 Abstract Background GH and IGFs serum levels decline with age. Age-related changes appear to be associated to decreases in these anabolic hormones. We have previously demonstrated that IGF-I replacement therapy improves insulin resistance lipid metabolism and reduces oxidative damage in brain and liver in aging rats. Using the same experimental model the aim of this work was to study whether the exogenous administration of IGF-II at low doses acts analogous to IGF-I in aging rats. Methods Three experimental groups were included in this study young healthy controls yCO 17 weeks old untreated old rats O 103 weeks old and aging rats treated with IGF-II O IGF-II 2 gg 100 g body weight-1 day-1 for 30 days. Analytical parameters were determined in serum by routine laboratory methods using an autoanalyzer Cobas Mira Roche Diagnostic System Basel Switzerland . Serum levels of hormones testosterone IGF-I and insulin were assessed by RIA. Serum Total Antioxidant Status was evaluated using a colorimetric assay. Mitochondrial membrane potential was evaluated using rhodamine 123 dye adding different substrates to determine the different states . ATP synthesis in isolated mitochondria was determined by an enzymatic method. Results Compared with young controls untreated old rats showed a reduction of IGF-I and testosterone levels with a decrease of serum total antioxidant status TAS . IGF-II therapy improved serum antioxidant capability without modifying testosterone and IGF-I circulating concentrations. In addition IGF-II treatment reduced oxidative damage in brain and liver improving .